Literature DB >> 18761091

Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.

Niklas Thon1, Karin Damianoff, Jemima Hegermann, Stefan Grau, Bjarne Krebs, Oliver Schnell, Jörg-Christian Tonn, Roland Goldbrunner.   

Abstract

BACKGROUND: Presence of CD133(+) cancer stem cells has been demonstrated within glioblastoma multiforme (GBM), the most malignant phenotype of gliomas (WHO grade IV). Since GBM frequently develops from low grade gliomas (WHO grade II) we assessed a possible qualitative or quantitative correlation of CD133(+) cells and glioma grade to get new insights in gliomagenesis.
RESULTS: The amount of CD133(+) cells within the bulk tumor mass, analyzed by immunostaining and Western blotting, showed a clear quantitative correlation with glioma grade (WHO degrees II, III and IV). Most of CD133(+) cells were arranged in clusters frequently associated to tumor vessels. Protein analysis revealed high cellular coexpression of CD133 with Musashi-I but not CD34 indicating a neural, i.e. local origin of these cells. In vitro, no differences in stem cell properties concerning self-renewal and multi-lineage differentiation have been found for CD133(+) cells isolated from gliomas of different grades.
CONCLUSIONS: These findings indicate a solely quantitative correlation of glioma grade with the presence of neural CD133(+) cells within tumors supporting the concept of a CD133(+) stem cell dependent gliomagenesis. Copyright 2008. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761091     DOI: 10.1016/j.mcn.2008.07.022

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  42 in total

1.  CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.

Authors:  Joseph G Pressey; Marilyn C Haas; Christine S Pressey; Virginia M Kelly; Jacqueline N Parker; G Yancey Gillespie; Gregory K Friedman
Journal:  Pediatr Blood Cancer       Date:  2012-03-09       Impact factor: 3.167

2.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

3.  Malignant clinical features of anaplastic gliomas without IDH mutation.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Takuhiro Shoji; Masayuki Kanamori; Ryuta Saito; Tomoo Inoue; Tomohiro Kawaguchi; Yoji Yamashita; Takashi Watanabe; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2014-06-23       Impact factor: 12.300

4.  Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.

Authors:  Jung Ha Shin; Youn Soo Lee; Yong-Kil Hong; Chang Suk Kang
Journal:  J Neurooncol       Date:  2013-10-16       Impact factor: 4.130

5.  Clinical value of CD133 and nestin in patients with glioma: a population-based study.

Authors:  Rikke H Dahlrot; Steinbjørn Hansen; Stine S Jensen; Henrik D Schrøder; Jacob Hjelmborg; Bjarne W Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 6.  NF-kappaB and STAT3 signaling in glioma: targets for future therapies.

Authors:  George P Atkinson; Susan E Nozell; Etty Tika N Benveniste
Journal:  Expert Rev Neurother       Date:  2010-04       Impact factor: 4.618

7.  Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.

Authors:  Ulrich Jarry; Cynthia Chauvin; Noémie Joalland; Alexandra Léger; Sandrine Minault; Myriam Robard; Marc Bonneville; Lisa Oliver; François M Vallette; Henri Vié; Claire Pecqueur; Emmanuel Scotet
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

8.  In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.

Authors:  Alexandra K Bohm; Jessica DePetro; Carmen E Binding; Amanda Gerber; Nicholas Chahley; N Dan Berger; Mathaeus Ware; Kaitlin Thomas; U Senapathi; Shazreh Bukhari; Cindy Chen; Erin Chahley; Cameron Grisdale; Sam Lawn; Yaping Yu; Raymond Wong; Yaoqing Shen; Hiba Omairi; Reza Mirzaei; Nourah Alshatti; Haley Pedersen; Wee Yong; Samuel Weiss; Jennifer Chan; P J Cimino; John Kelly; Steve Jones; Eric Holland; Michael Blough; Gregory Cairncross
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 9.  The bright and the dark sides of DNA repair in stem cells.

Authors:  Guido Frosina
Journal:  J Biomed Biotechnol       Date:  2010-04-08

10.  A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles.

Authors:  Laura K Donovan; Nicola E Potter; Tracy Warr; Geoffrey J Pilkington
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.